Mylan Accuses Warner, Mayne Of Plot To Delay Generics

Law360, New York (July 9, 2012, 4:50 PM EDT) -- Mylan Pharmaceuticals Inc. on Friday accused Warner Chilcott PLC and Mayne Pharma Group Ltd. of conspiring to prevent and delay generic competition to its anti-acne and bacterial infection drug Doryx by making minor changes to the drug every few years, with no real benefit.

Mylan claims that since as early as 2005, Warner Chilcott and Mayne have unlawfully interfered with the regulatory process, causing delays in the approval of generic versions of Doryx and disrupting the market for the generic drug, violating the Sherman Act by...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.